论文部分内容阅读
目的比较伊立替康联合顺铂和伊立替康联合洛铂方案二线治疗广泛期小细胞肺癌的客观疗效及不良反应。方法回顾分析2011年1月至2013年12月间内蒙古包头市肿瘤医院收治的56例复发转移的小细胞肺癌的临床资料,根据患者接受不同治疗方案分为伊立替康联合顺铂方案(IP组)和伊立替康联合洛铂方案(IL)组,每组28例。记录临床近期疗效及治疗3周后的不良反应。结果 IP组有效率为28.6%,疾病控制率为57.1%。IL组有效率为25.0%,疾病控制率为60.7%,两组相比,差异无统计学意义(P>0.05)。IL组胃肠道不良反应明显低于IP组,差异有统计学意义(P<0.05)。结论伊立替康联合顺铂和(或)洛铂二线治疗广泛期小细胞肺癌具有较高的临床有效率,联合洛铂不良反应较轻。
Objective To compare the curative effects and side effects of irinotecan plus cisplatin and irinotecan combined with lobaplatin in the second-line treatment of extensive stage small cell lung cancer. Methods The clinical data of 56 patients with recurrent metastatic small cell lung cancer admitted to Baotou Tumor Hospital in Inner Mongolia from January 2011 to December 2013 were retrospectively analyzed. According to the different treatment regimens, patients were divided into irinotecan plus cisplatin regimen (IP group ) And irinotecan combined with lobaplatin program (IL) group, 28 cases in each group. Record the clinical efficacy and treatment of adverse reactions after 3 weeks. Results The effective rate of IP group was 28.6% and disease control rate was 57.1%. The effective rate of IL was 25.0% and the disease control rate was 60.7%. There was no significant difference between the two groups (P> 0.05). The gastrointestinal adverse reactions in IL group were significantly lower than those in IP group, the difference was statistically significant (P <0.05). Conclusion Irinotecan plus cisplatin and (or) lobaplatin second-line treatment of extensive stage of small cell lung cancer has a high clinical efficiency, combined with low adverse reactions lorazepam.